For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo and Ranbaxy to Expand Hybrid Business Model in Mexico

Tokyo Japan and Gurgaon India (August 2, 2011) -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced the expansion of business in Mexico to maximize their Hybrid Business Model, encompassing both innovative and affordable, high quality, generic medicines.

Daiichi Sankyo and Ranbaxy (collectively “the Group”) have agreed to expand the Group’s business in Mexico with the launch of Olmesartan medoxomil. The product is expected to be introduced to the market before the end of 2011. Daiichi Sankyo Mexico S.A. de C.V (DSMX), a newly established subsidiary of Daiichi Sankyo, and Ranbaxy Mexico S.A de C.V. (RMEX) will leverage the Group’s Hybrid Business Model in Mexico by utilizing the business know-how and cost advantage of Ranbaxy, thereby offering both innovative and affordable, high quality generic medicines.

“We are pleased to announce the synergistic business development with Ranbaxy in Mexico,” said Joji Nakayama, President & CEO of Daiichi Sankyo. “We are determined to work with Ranbaxy to further serve diversifying medical needs in this strongly emerging market.”

Commenting on the development, Arun Sawhney, Managing Director of Ranbaxy, said, “Mexico is an important emerging market for us, and Ranbaxy and Daiichi Sankyo will work together in providing innovative options and solutions to customers through the Hybrid Business Model.”

Daiichi Sankyo and Ranbaxy will continue to reinforce their respective and consolidated business platforms over the longer term by further accelerating their global business coordination.

 

About Olmesartan medoxomil

Olmesartan medoxomil is a member of the angiotensin receptor blocker (ARB) class of antihypertensive medications that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonizing the release of the hormone which causes salt retention and increased blood volume. Olmesartan medoxomil is available in more than 60 countries worldwide.

 

About RMEX

RMEX, a subsidiary of Ranbaxy, has already been delivering a strong portfolio of generic medicines for a wide range of therapeutic segments in Mexico. In October 2009, RMEX created a division for the future introduction of Daiichi Sankyo's innovator products into the Mexican market. With an estimated population of 107 million people, Mexico is the 14th largest pharmaceutical market in the world, and is the second largest in Latin America. The size of the pharmaceutical market in Mexico is approximately USD $11.4 billion (2010).

 

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com

 

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.